[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-detail-12908":3,"doc-seo-12908":27},{"code":4,"msg":5,"data":6},0,"success",{"doc_id":7,"user_id":8,"nickname":9,"user_avatar":10,"doc_module":4,"category_id":11,"category_name":12,"doc_title":13,"doc_description":14,"file_id":15,"file_url":16,"file_type":17,"file_size":18,"view_count":19,"is_deleted":4,"is_public":20,"is_downloadable":20,"audit_status":20,"page_count":21,"language":22,"language_code":23,"table_of_contents":24,"faqs":24,"seo_title":13,"seo_description":14,"update_tm":25,"read_time":26},12908,4398048950312,"Violet","https://ap-avatar.wpscdn.com/avatar/400002538284de19e3c?_k=1778320343897328908",7,"Healthcare","Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: multicentre, double-blind, randomised, controlled trial","Ferric carboxymaltose administered after stabilization from acute heart failure in iron-deficient patients was compared with placebo in a multicentre, double-blind, randomized trial. The composite of heart-failure hospitalisations and cardiovascular death showed no clear difference overall, while ferric carboxymaltose reduced total heart-failure hospitalisations and delayed the first heart-failure hospitalisation or cardiovascular death. No difference was seen in cardiovascular death. Treatment was generally safe.","cbCaitbluMj4mk4u","https://ap.wps.com/l/cbCaitbluMj4mk4u","pdf",746961,5,1,10,"English","en","",1776448972,25,{"code":4,"msg":28,"data":29},"ok",{"site_id":30,"language":23,"slug":31,"title":13,"keywords":24,"description":14,"schema_data":32,"social_meta":67,"head_meta":70,"extra_data":72,"updated_unix":25},105,"ferric-carboxymaltose-for-iron-deficiency-at-discharge-after-acute-heart-failure-multicentre-double-blind-randomised-controlled-trial",{"@graph":33,"@context":66},[34,51],{"@type":35,"itemListElement":36},"BreadcrumbList",[37,41,45,48],{"item":38,"name":39,"@type":40,"position":20},"https://docshare.wps.com","Home","ListItem",{"item":42,"name":43,"@type":40,"position":44},"https://docshare.wps.com/document/","Document",2,{"item":46,"name":12,"@type":40,"position":47},"https://docshare.wps.com/document/healthcare/",3,{"item":49,"name":13,"@type":40,"position":50},"https://docshare.wps.com/document/ferric-carboxymaltose-for-iron-deficiency-at-discharge-after-acute-heart-failure-multicentre-double-blind-randomised-controlled-trial/12908/",4,{"url":49,"name":13,"@type":52,"author":53,"headline":13,"publisher":55,"fileFormat":58,"description":14,"dateModified":59,"datePublished":60,"encodingFormat":58,"isAccessibleForFree":61,"interactionStatistic":62},"DigitalDocument",{"name":9,"@type":54},"Person",{"url":38,"name":56,"@type":57},"DocShare","Organization","application/pdf","2026-06-02","2026-04-17",true,{"@type":63,"interactionType":64,"userInteractionCount":19},"InteractionCounter",{"@type":65},"ViewAction","https://schema.org",{"og:url":68,"og:type":69,"og:title":13,"og:site_name":56,"og:description":14},"https://docshare.wps.com/document/ferric-carboxymaltose-for-iron-deficiency-at-discharge-after-acute-heart-failure-multicentre-double-blind-randomised-controlled-trial/12908","article",{"robots":71,"canonical":68},"index,follow",{"doc_id":7,"site_id":30}]